Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide with enormous social and economic cost implications. The ideal strategy for altering such a trend is optimum primary prevention. The European Society of Cardiology (ESC) guidelines 1 and recent American Heart Association/ American College of Cardiology (AHA/ACC) guidelines for CVD prevention 2 stress the central role of promoting a healthy lifestyle throughout life. The two guidelines recommend assessing conventional cardiovascular risk factors and calculate the 10-year risk of fatal CVD or 10-year probability of developing a first major cardiovascular event (myocardial infarction or stroke) by using the risk charts or scores. However, the benefit of using current CVD risk estimation models is limited. The use of the available tools, such as the SCORE of the ESC, may lead to serious underor over-estimation of cardiovascular risk, particularly in asymptomatic subjects considered at intermediate risk for events. Also, selected groups, such as young people and women, require special consideration for risk stratification. 3 Based on this, the ESC guidelines for CVD prevention proposed other factors that should be considered in order to better classify individuals into more appropriate risk categories. Among these factors is the search for objective evidence for subclinical atherosclerosis, such as coronary calcification and its score obtained by computed tomography (CT) or atherosclerotic plaque detection and measurements obtained from carotid artery ultrasound scans.
Coronary artery scanning performed using cardiac CT and calculation of the Agatston calcium score is the most commonly used technique in clinical practice for detection of subclinical atherosclerosis, prognostic stratification of asymptomatic individuals and implementation of preventive strategies. Furthermore, like a coronary calcium score, a routine echocardiographic examination may offer an indirect evaluation of subclinical atherosclerosis disease by semi-quantitative assessment of cardiac calcifications at different sites, including the mitral apparatus (annulus, leaflets and papillary muscles), aortic valve and ascending aorta, that have been shown to predict future major coronary events, major cardiovascular events and mortality in asymptomatic subjects. 4, 5 The Multi-Ethnic Study of Atherosclerosis, a population-based cohort with no known cardiovascular disease, reported the accuracy of coronary artery calcium score in predicting clinical events. A calcium score greater than 300 accurately identified subjects at high risk for future coronary heart disease events, with a hazard ratio of nearly 10.
6,7 Likewise, visualization of asymptomatic subclinical carotid atherosclerosis can improve an individual's risk classification and consequently guide towards a tailored optimum prevention strategy, one of the most important being lipid lowering therapy, and the eligibility for statin therapy. In 'The BioImage Study', 8 Mortensen et al. proposed a personalized approach to primary prevention with statins by adding an 'imagingguided' reclassification step after risk assessment using the Pooled Cohort Equation, as recommended in AHA/ACC guidelines. Subjects with initial indication for statin therapy underwent a re-stratification of their risk according to the presence of coronary artery calcium on CT or carotid plaque on ultrasound scan. This revised classification significantly improved the individual allocation to statin treatment. Thus, the accurate identification of high risk individuals using an approach that integrates the conventional atherosclerosis risk factor score and the imaging of subclinical atherosclerosis should not only allow appropriate use of pharmacological interventions in primary prevention but also support the prescription of a healthy lifestyle, such as physical activity, weight reduction, stress control, et cetera. In fact, healthy lifestyle remains the cornerstone of primary prevention. However, despite the fact that all guidelines emphasize the role of a healthy lifestyle in cardiovascular prevention and encourage medical organizations to tailor patient education and to share decision-making and patientcentred strategies of care to ensure adherence, the data remain disappointing. 1, 9, 10 So, why does prevention fail? The likely answer to this question is probably to do with the inefficiency of the current strategies of information delivery and lack of optimum education that should lead to changing harmful behaviors. Standardized and verbally delivered information alone rarely lead to effective lifestyle change. However, a personalized approach towards highlighting individuals' risks, race, 11 arterial health status and available methods for improving it should have a significant impact on patients' adherence to clinical, pharmacological and lifestyle instructions. This approach was investigated in the VIPVIZA trial, recently published in the Lancet. 12 This study evaluated a large cohort of adults free from cardiac diseases but with one or more conventional cardiovascular risk factors who underwent a carotid ultrasound scan for atherosclerotic plaque or increased intima-media thickness. 12 Individuals were randomized to receive a pictorial presentation of their carotid ultrasound results; in particular, carotid plaque was shown and described, with written information about atherosclerosis as a dynamic disease, modifiable by a healthy lifestyle and pharmacological treatment (intervention group) versus traditional management (control group). After one-year follow-up, the intervention group showed a significant improvement of cardiovascular risk profile, as assessed by the Framingham risk score, a slight decrease in weight, a significant increase in use of lipid-lowering drugs and better adherence to antihypertensive medications compared with controls. 12 In the current issue of the European Journal of Preventive Cardiology, there are interesting data supporting new approaches to improve subjects' education toward a healthy lifestyle in a sub-study from the Dutch Risk Or Benefit IN Screening for CArdiovascular disease (ROBINSCA) trial. 13 The ROBINSCA trial is a large population-based randomized controlled screening trial designed to investigate the difference between the traditional assessment of CVD risk, by means of the SCORE risk table, and an evaluation based on coronary artery calcification score performed by CT scanning. The study included a sub-analysis where both groups of participants received an online questionnaire to investigate prevention-seeking behaviour and compliance to preventive treatment. The results of this study show that more subjects with high coronary artery calcium score contacted their general practitioners, seeking advice, compared with those with high SCORE risk alone. Furthermore, a higher percentage of those who sought advice were commenced on risk factors controlling medications, antihypertensive and cholesterol lowering drugs, compared with controls. 13 The results of the study suggest that the optimum perception of cardiovascular risk that the individuals carry, particularly when clearly demonstrated to them using non-invasive tools of imaging subclinical atherosclerosis, plays an important role in encouraging adherence to medical treatment and lifestyle changes. The evidence is building up in supporting the invaluable role of sharing arterial imaging evidence of subclinical atherosclerosis with asymptomatic individuals carrying cardiovascular risks as an objective means for achieving better risk control and certainly satisfactory clinical outcome.
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